The cost of Opzelura (ruxolitinib cream) without insurance can vary significantly depending on factors such as the strength of the prescription, the quantity dispensed, and the pharmacy. However, it is generally considered a high-cost medication.
How much does Opzelura cost without insurance?
While a definitive out-of-pocket price without insurance is difficult to state universally, the list price for Opzelura is substantial. For example, a 60-gram tube of 1.5% Opzelura has a list price that can exceed $2,000. These figures are subject to change and may differ between pharmacies and geographic locations.
What financial assistance programs are available for Opzelura?
For patients without insurance or with high copayments, pharmaceutical manufacturers often provide patient assistance programs to help offset the cost of their medications. Opzelura's manufacturer, Incyte, offers a program called IncyteCARES for Patients. This program may provide copay assistance for eligible commercially insured patients and, in some cases, offers free medication for uninsured or underinsured patients who meet specific criteria. Information on eligibility and how to apply is available through the IncyteCARES program.
How does Opzelura's price compare to other topical treatments for atopic dermatitis?
Opzelura is a prescription topical medication. Other prescription topical treatments for conditions like atopic dermatitis may include corticosteroids or other non-steroidal agents, which can also have varying costs. The price of Opzelura is generally in line with other newer, targeted therapies for chronic skin conditions.
What is the mechanism of action for Opzelura?
Opzelura is a Janus kinase (JAK) inhibitor. It works by inhibiting specific enzymes (JAK1 and JAK2) involved in the signaling pathways that contribute to inflammation and itching associated with certain skin conditions [1]. By reducing this inflammation, it aims to improve the signs and symptoms of these dermatological issues.
What conditions is Opzelura approved to treat?
Opzelura is approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in adult and pediatric patients 12 years of age and older [1].
When does the patent for Opzelura expire?
Information regarding patent expiration dates for specific drugs, including Opzelura, is tracked and updated by patent watch services. According to DrugPatentWatch.com, the patent protection for Opzelura (ruxolitinib cream) is an important consideration for its market exclusivity [2]. Specific patent expiry dates can be complex and subject to legal challenges or extensions.
Sources:
1. Opzelura Prescribing Information
2. DrugPatentWatch.com